Spero Therapeutics (NASDAQ:SPRO – Get Rating) had its price target trimmed by HC Wainwright from $7.00 to $6.00 in a research note released on Monday morning, The Fly reports. The firm currently has a buy rating on the stock.

Separately, Evercore ISI raised shares of Spero Therapeutics from an in-line rating to an outperform rating and set a $8.00 price objective for the company in a research report on Thursday, September 22nd. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Spero Therapeutics presently has an average rating of Hold and an average target price of $6.33.

Spero Therapeutics Price Performance

SPRO stock opened at $1.97 on Monday. Spero Therapeutics has a 52-week low of $0.68 and a 52-week high of $18.84. The company has a 50-day moving average of $1.03 and a two-hundred day moving average of $2.56. The stock has a market capitalization of $69.08 million, a price-to-earnings ratio of -0.57 and a beta of 1.87.

Insider Activity

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SPRO. Kingsbury Capital Investment Advisors LLC acquired a new position in Spero Therapeutics in the second quarter worth about $45,000. Engineers Gate Manager LP acquired a new stake in shares of Spero Therapeutics during the first quarter worth approximately $95,000. Assenagon Asset Management S.A. increased its holdings in shares of Spero Therapeutics by 466.6% during the second quarter. Assenagon Asset Management S.A. now owns 131,020 shares of the company's stock worth $97,000 after buying an additional 107,897 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Spero Therapeutics during the second quarter worth approximately $115,000. Finally, XTX Topco Ltd bought a new stake in shares of Spero Therapeutics during the first quarter valued at approximately $115,000. Institutional investors and hedge funds own 57.38% of the company's stock.

About Spero Therapeutics

(Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Featured Stories

• Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
• Humana Proves Vertically Integrated Healthcare Works
• What Cintas Can Teach Investors About This Bear Market?
• 2 Casino Stocks Worth Taking a Look At
• This Small-Cap Healthcare Name Is Outperforming Its Index
• Blackberry Stock Declines As Results Come In Lukewarm Once Again

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.